Original Articles
Vol. 60 No. 4 (2008)
https://doi.org/10.4081/reumatismo.2008.290

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2361
Views
1230
Downloads

Authors

P. Sarzi- Puttini
office@pagepress.org
, Italy.
M. Antivalle
, Italy.
A. Marchesoni
, Italy.
E.G. Favalli
, Italy.
R. Gorla
, Italy.
M. Filippini
, Italy.
R. Caporali
, Italy.
F. Bobbio-Pallavicini
, Italy.
C. Montecucco
, Italy.
F. Atzeni
, Italy.
Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients...

Downloads

Download data is not yet available.

How to Cite



1.
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo [Internet]. 2008 Dec. 30 [cited 2026 Sep. 11];60(4):290-5. Available from: https://www.reumatismo.org/reuma/article/view/reumatismo.2008.290

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.